Keytruda

Keytruda. It is a humanized monoclonal antibody used in cancer immunotherapy, developed and marketed by the pharmaceutical company Merck & Co.. Known generically as pembrolizumab, it functions as an immune checkpoint inhibitor, specifically targeting the programmed cell death protein 1 (PD-1) receptor on T cells. Its approval by the U.S. Food and Drug Administration in 2014 marked a significant advancement in the treatment of several malignancies, including melanoma and non-small cell lung carcinoma.

Medical uses

Keytruda is indicated for the treatment of a wide array of cancers, having received numerous approvals from regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency. Its primary uses include advanced melanoma, non-small cell lung carcinoma, head and neck squamous cell carcinoma, and classical Hodgkin lymphoma. It is also approved for cancers with specific biomarkers, such as microsatellite instability-high or mismatch repair deficient solid tumors, regardless of the organ of origin. Furthermore, it is used in combination with chemotherapy for certain cancers like triple-negative breast cancer and is a standard treatment for renal cell carcinoma alongside axitinib. Ongoing clinical trials at institutions like the National Cancer Institute continue to expand its applications to other malignancies.

Mechanism of action

The therapeutic effect of Keytruda is achieved through its blockade of the programmed cell death protein 1 (PD-1) pathway, a critical immune checkpoint. PD-1 is a receptor expressed on the surface of activated T cells, and its interaction with ligands such as PD-L1 and PD-L2, often found on tumor cells, transmits an inhibitory signal that suppresses T cell-mediated immune responses. By binding to the PD-1 receptor, Keytruda prevents this interaction, thereby releasing the brakes on the immune system and allowing cytotoxic T cells to recognize and attack cancer cells. This mechanism of immune checkpoint inhibition represents a fundamental shift from traditional therapies like chemotherapy and radiation therapy, which directly target the tumor.

Adverse effects

As an immune checkpoint inhibitor, Keytruda can cause immune-related adverse events due to the enhanced activity of the immune system against normal tissues. Common side effects include fatigue, rash, pruritus, diarrhea, and decreased appetite. More serious, potentially life-threatening complications can involve any organ system, such as pneumonitis, colitis, hepatitis, endocrinopathies like hypothyroidism or adrenal insufficiency, and severe skin reactions like Stevens-Johnson syndrome. The management of these events often requires collaboration with specialists and may involve the use of corticosteroids like prednisone or therapy interruption, as outlined in guidelines from the American Society of Clinical Oncology.

History and development

The development of Keytruda originated from research into the PD-1 pathway by scientists including Tasuku Honjo, who later shared the Nobel Prize in Physiology or Medicine for this discovery. Merck & Co. acquired the compound through its purchase of Schering-Plough and advanced it through clinical trials. It received its first accelerated approval from the U.S. Food and Drug Administration in September 2014 for advanced melanoma, following pivotal studies presented at meetings of the American Society of Clinical Oncology. Subsequent approvals expanded its use to lung cancer, making it a blockbuster therapy and a cornerstone of modern oncology. Its development was also influenced by earlier work on ipilimumab, another immune checkpoint inhibitor targeting CTLA-4.

Society and culture

Keytruda has had a profound impact on oncology and popular culture, often cited as a breakthrough in the "war on cancer." Its high cost has sparked significant debate about drug pricing and access to healthcare, involving entities like the National Health Service in the United Kingdom and insurance providers in the United States. The drug has been featured in media, including the memoir "The Emperor of All Maladies" and subsequent documentary, highlighting the evolution of cancer treatment. Patient advocacy groups, such as those for melanoma research, have been instrumental in promoting awareness and access. Furthermore, the role of Tasuku Honjo and the Nobel Prize brought significant public attention to the field of immunotherapy.

Category:Monoclonal antibodies Category:Antineoplastic drugs Category:Merck & Co.